June 8 (Reuters) - The actions of Novavax Inc (nvax.O) jumped almost 20% on Wednesday after the advisers

of the Food and Drug Administration massively supported the use of its COVVI -19 vaccine, bringing the shooting

Closer of an American launch. On Friday, the stock dropped by around 20% after Heath regulator examiners reported

the concerns of a type of cardiac inflammation after vaccination, adding uncertainty on the outcome of Tuesday's meeting.

However, the vote of external advisers - 21 for, no against and 1 abstention - indicates that the FDA could soon authorize

the fourth vaccine in the United States, where Novavax hopes that it would become the choice of the skeptics of the vaccine.

the fourth vaccine in the United States, where Novavax hopes that it would become the choice of the skeptics of the vaccine.

Said Novavax CEO, Stanley Erck on Tuesday. The voting of the FDA panel is a positive development for Novavax

Said analysts, because it reduces uncertainty around a vaccine that has had a long way to authorization.

Swipe Up to Read More Story

Swipe Up